Stock IVRN INNOVEREN SCIENTIFIC INC.
Add to a list
To use this feature you must be a member
Log inSign up

Innoveren Scientific Inc. Share Price

Equities

IVRN

US4041243076

Advanced Medical Equipment & Technology

Market Closed - OTC Markets
Other stock markets
 16:46:52 17/04/2024 BST 		5-day change 1st Jan Change
0.02 USD -33.33% Intraday chart for Innoveren Scientific Inc. 0.00% -82.76%
03-06 Innoveren Scientific Announces 510(K) Submission to U.S. Federal Food and Drug Administration for Skindisc(Tm) Lite CI
2023 Innoveren Scientific Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI

Financials

Sales 2021 1.61M 129M Sales 2022 453K 36.21M Capitalization 1.62M 129M
Net income 2021 -4M -319M Net income 2022 -10M -799M EV / Sales 2021 7.95 x
Net Debt 2021 3.52M 281M Net Debt 2022 3.92M 313M EV / Sales 2022 12.2 x
P/E ratio 2021
-1.73 x
P/E ratio 2022
-0.08 x
Employees -
Yield 2021 *
-
Yield 2022
-
Free-Float 35.62%
More Fundamentals * Assessed data

Chart Innoveren Scientific Inc.

Dynamic Chart

Latest news about Innoveren Scientific Inc.

Innoveren Scientific Announces 510(K) Submission to U.S. Federal Food and Drug Administration for Skindisc(Tm) Lite CI
Innoveren Scientific Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Innoveren Scientific Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
H-Cyte, Inc. has Changed its Name to Innoveren Scientific Inc CI
Innoveren Scientific Inc. has Changed its Ticker to IVRN from HCYT CI
H-CYTE, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
H-CYTE, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
H-CYTE, Inc. Auditor Raises 'Going Concern' Doubt CI
H-CYTE, Inc. announced that it expects to receive $0.135 million in funding CI
H-CYTE, Inc. announced that it expects to receive $0.3 million in funding CI
H-CYTE, Inc. (OTCQB: HCYT) completed the acquisition of SkinDisc from Tanya Rhodes, Brock Liden, Spencer T Brown and Spencer T Brown. CI
H-CYTE, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
H-CYTE, Inc. announced that it has received $0.225 million in funding CI
H-CYTE, Inc. (OTCQB: HCYT) entered into a letter of intent to acquire SkinDisc from Tanya Rhodes, Brock Liden, Spencer T Brown and Spencer T Brown for $2.3 million. CI
H-CYTE, Inc. cancelled the acquisition of Catheter Precision, Inc. CI
More news

Press releases Innoveren Scientific Inc.

H-CYTE, INC. : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregistered Sale of Equity Securities, Financial Statements and Exhibits (form 8-K) AQ
H-CYTE, INC. : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregistered Sale of Equity Securities, Financial Statements and Exhibits (form 8-K) AQ
H-CYTE Completes Acquisition of SkinDisc™ Regenerative Tissue Kit from Scion Solutions, LLC AQ
H-CYTE, INC. : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Financial Statements and Exhibits (form 8-K) AQ
H-CYTE, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q) AQ
More press releases

Quotes and Performance

1 day-33.33%
Current month-39.39%
1 month-39.39%
3 months-69.23%
6 months+6,566.67%
Current year-82.76%
More quotes

Highs and lows

1 month
0.00
Extreme 0.0003
0.06
Current year
0.00
Extreme 0.0003
0.18
1 year
0.00
Extreme 0.0003
3.73
3 years
0.00
Extreme 0.0003
289.00
5 years
0.00
Extreme 0.0003
990.00
10 years
0.00
Extreme 0.0003
990.00
More quotes

Managers and Directors - Innoveren Scientific Inc.

Managers TitleAgeSince
Michael Yurkowsky CEO
 Chief Executive Officer 53 07/01/19
Jeremy Daniel DFI
 Director of Finance/CFO 48 03/02/19
Tanya Rhodes CTO
 Chief Tech/Sci/R&D Officer 64 14/06/20
Members of the board TitleAgeSince
Richard Rosenblum BRD
 Director/Board Member 65 16/01/22
Michael Yurkowsky CEO
 Chief Executive Officer 53 07/01/19
William E. Horne BRD
 Director/Board Member 70 08/10/18
More insiders

Company Profile

Innoveren Scientific Inc. is a life science and biotech incubator company. The Company is focused on advancing new technologies in areas of unmet need across multiple indications for improving patient lives. The Company is also focused on investing in and fosters technologies that are supported by a scientific foundation.
Sector
Advanced Medical Equipment & Technology
More about the company

Income Statement Evolution

More financial data

Sector Other Advanced Medical Equipment & Technology

1st Jan change Capi.
INNOVEREN SCIENTIFIC INC. Stock Innoveren Scientific Inc.
-82.76% 107K
THERMO FISHER SCIENTIFIC Stock Thermo Fisher Scientific
+8.07% 219B
DANAHER CORPORATION Stock Danaher Corporation
+6.59% 183B
INTUITIVE SURGICAL, INC. Stock Intuitive Surgical, Inc.
+11.26% 133B
BOSTON SCIENTIFIC CORPORATION Stock Boston Scientific Corporation
+26.57% 108B
SIEMENS HEALTHINEERS AG Stock Siemens Healthineers AG
+0.65% 63.06B
EDWARDS LIFESCIENCES CORPORATION Stock Edwards Lifesciences Corporation
+13.35% 52.02B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD. Stock Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
-0.62% 48.2B
AGILENT TECHNOLOGIES, INC. Stock Agilent Technologies, Inc.
-0.93% 40.37B
GE HEALTHCARE TECHNOLOGIES INC. Stock GE HealthCare Technologies Inc.
+11.54% 39.35B
Other Advanced Medical Equipment & Technology
  1. Stock Market
  2. Equities
  3. IVRN Stock